Clinical Research Directory
Browse clinical research sites, groups, and studies.
Effects of a Prebiotic-Probiotic Combination on Constipation Symptoms and Quality of Life
Sponsor: Seoul National University Hospital
Summary
This study aims to evaluate whether a combination of a prebiotic (1-kestose) and a probiotic (Lacticaseibacillus rhamnosus BBH112) improves gastrointestinal symptoms and quality of life in adults with constipation-related symptoms. A total of 40 adults aged 19 to 80 years will be enrolled in this randomized, double-blind, controlled trial. Participants will be randomly assigned to receive either the probiotic combined with the prebiotic or the probiotic combined with a placebo for 8 weeks. The primary objective is to compare overall satisfaction with gastrointestinal symptom improvement between the two groups after 8 weeks. The study will also assess changes in abdominal pain, bloating, bowel habits, stool consistency, quality of life, and psychological well-being. In addition, changes in the gut microbiome will be evaluated using stool samples collected before and after the intervention. The findings may help determine whether adding a prebiotic to probiotic supplementation provides additional benefits for adults experiencing constipation-related gastrointestinal symptoms.
Official title: Effects of a Prebiotic-Probiotic Combination on Gastrointestinal Symptoms and Quality of Life in Individuals With Constipation: A Randomized, Double-Blind, Controlled Trial
Key Details
Gender
All
Age Range
19 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2026-07-10
Completion Date
2027-01-15
Last Updated
2026-11-06
Healthy Volunteers
No
Interventions
Lacticaseibacillus rhamnosus BBH112
Lacticaseibacillus rhamnosus BBH112 is a probiotic strain isolated from a healthy human donor. The probiotic is administered orally as two capsules once daily for 8 weeks. Each capsule contains 1 × 10\^10 colony-forming units (CFU) of L. rhamnosus BBH112, providing a total daily dose of 2 × 10\^10 CFU. Participants in both the experimental and active comparator groups will receive this probiotic supplementation.
1-Kestose (GF2)
1-Kestose (GF2) is a prebiotic fructooligosaccharide with a purity of at least 98%. Participants assigned to the experimental group will receive 1-kestose powder orally at a dose of 5 g twice daily (total daily dose of 10 g) for 8 weeks, in combination with Lacticaseibacillus rhamnosus BBH112. The intervention aims to evaluate the additional effects of prebiotic supplementation on constipation-related gastrointestinal symptoms, bowel habits, quality of life, and gut microbiome composition.
Dextrin Placebo Powder
Participants assigned to the active comparator group will receive placebo powder orally at a dose of 5 g twice daily (total daily dose of 10 g) for 8 weeks, in combination with Lacticaseibacillus rhamnosus BBH112. The placebo will be administered under blinded conditions to allow comparison with the prebiotic intervention.
Locations (1)
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea